Severe Progressive Subcutaneous Abscesses and Necrotizing Tenosynovitis Caused by *Rhodococcus aurantiacus*

MICHIO TSUKAMURA,¹* KAZUO HIKOSAKA,² KENICHIRO NISHIMURA,² AND SUSUMU HARA³

National Chubu Hospital, Obu, Aichi 474,¹ and Department of Orthopedics, Fujita Gakuen Health University Medical School,² and Central Laboratories, Fujita Gakuen Health University,³ Toyoake, Aichi 470-11, Japan

Received 24 August 1987/Accepted 9 October 1987

A case of severe progressive subcutaneous abscesses and necrotizing tenosynovitis of the right arm of a 30-year-old woman caused by *Rhodococcus aurantiacus* is reported.

Rhodococcus aurantiacus was reported by Tsukamura and Mizuno (6) as *Gordona aurantiaca*. The name was changed to *R. aurantiacus* (7). However, this taxon differs from other rhodococci by several characteristics (3, 7). A case of lung infection caused by this organism was reported by Tsukamura and Kawakami (5), and a case of lethal meningitis was reported by Prinz et al. (1). Here, we report the third case of infection caused by this organism.

CASE REPORT

The patient was a 30-year-old female (school teacher). In May 1981, she felt pain in her right forearm and was diagnosed as suffering from de Quervain disease (painful tenosynovitis due to relative narrowness of the common tendon sheath of the abductor pollicis longus and the extensor pollicis brevis). In September 1982, she visited our orthopedics clinic, since an incision of the right forearm performed elsewhere had not healed. We incised this surgical wound repeatedly to derive pus. The wound did not improve. Instead, multiple abscesses, necrotizing tenosynovitis, and muscle necrosis of the right forearm developed. In November 1986, the right forearm was amputated. A month after this procedure, the amputation site showed signs of severe infection that progressed to involve the upper arm, leading to its amputation on 20 December 1986. In January 1987, the surgical wound again showed signs of infection, and pus was obtained by incision. At present, there is a fistula in the right shoulder that produces a small amount of pus continuously. During the entire period, the patient had slight fever, and the leukocyte count ranged from 6,000 to 12,000/mm³. No immunological abnormalities were found, including acquired immunodeficiency syndrome.

Originally, various bacteria were isolated from the pus on only one or two occasions. These were *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Peptococcus* sp., *Serratia liquefaciens*, *Klebsiella pneumoniae*, *Klebsiella* sp., *Pseudomonas aeruginosa*, *Pseudomonas fluorescens*, and *Enterobacter cloacae*. Fungi were not isolated. Since only a few colonies of these bacteria were recovered on isolation media, it was unlikely that they represented the cause of the disease. Examinations for acid-fast bacteria with Ogawa egg medium (4) after pretreatment with a 4% NaOH solution for 20 min were carried out repeatedly without recovery of mycobacteria. During the entire period of illness, various antibiotics were administered to the patient without success. The drugs included penicillins (amoxicillin, benzylpenicillin, piperacillin, carbenicillin, ampicillin, and sulbenicillin), cephalosporins (cefoperazone, cefaclor, cefazolin, ceftizoxime, and cefotaxime), cephamycin (cefmetazole), oxacephem (moxalactam), cephalexin, amikacin, gentamicin, minocycline, erythromycin, and norfloxacin. After the causative organism was found to be *R. aurantiacus*, we used a combination of ofloxacin (0.4 g daily), minocycline (200 mg daily), sulfadimethoxine (1.0 g daily), and rifampin (0.45 g daily), which were administered orally. However, until now, no marked improvement was achieved. Instead, the organism became resistant to 5 μ g of ofloxacin per ml 2 months after the beginning of the administration.

Histological examination of resected tissue specimens showed subcutaneous abscesses containing epitheloid cells and giant cells.

MATERIALS AND METHODS

Isolation of slightly acid-fast bacteria. From December 1986, pus specimens were examined by adding an equal volume of a 2% NaOH solution to the pus, followed by incubation at room temperature for 5 min. The mixture was inoculated on Ogawa egg medium slants with a pipette that delivers a 0.1-ml sample. The inoculated slants were incubated at 28°C for 7 days. Slightly acid-fast bacteria were isolated from the pus each time, and five isolates were obtained showing two or three colonies on the isolation medium. From March 1987, the pus mixture was inoculated with a spiral loop that delivers 0.02 ml of sample. The spiral loop was used to facilitate neutralization of the inoculated material on medium and to obtain better adhesion to the medium. From March to June 1987, six isolates were obtained by this method. The specimens showed from several to 60 colonies. Thus, a total of 11 isolates were studied.

Identification. The isolates were identified with 114 tests. Of these, 104 have been described previously (2). To these 104, the following 10 tests were added: Gram reactivity, growth at 42°C, utilization of L-serine as the sole nitrogen source, utilization of succinamide as the sole nitrogen source, resistance to 5% NaCl, resistance to isoniazid (10 μ g/ml), resistance to ofloxacin (1 μ g/ml), resistance to ofloxacin (20 μ g/ml), and resistance to mitomycin C (5 μ g/ml) (the resistance tests were performed in Ogawa egg medium). The results of the tests were read after incubation at 37°C for 7 days. The matching coefficient (*M* value) was calculated as the percent

^{*} Corresponding author.

202 TSUKAMURA ET AL.

| TABLE 1 | 1. 1 | Comparison | of the | characters of R | !. ai | urantiacus | and | other | rhodococci | i ^a |
|---------|------|------------|--------|-----------------|-------|------------|-----|-------|------------|----------------|
|---------|------|------------|--------|-----------------|-------|------------|-----|-------|------------|----------------|

| | % of strains with character? | | | | | | | | | | | |
|--|------------------------------|-------------------------|--------------------------------|------------------------------------|----------------------|---------------------|--|------------------------|------------------------------------|-------------------------|--------------------|--|
| Character | Present isolates $(n = 11)$ | R. aur-antiacus(n = 11) | R. bron- chialis (n = 7) | R. rubro- pertinctus $(n = 11)$ | R. terrae (n = 9) | R. sputi (n = 9) | $\begin{array}{l} R. \ aichiensis\\ (n=5) \end{array}$ | R. rho-dochrous(n = 5) | R. lenti- fragmentus (n = 9) | R. eryth-ropolis(n = 4) | R. equi (n = 8) | |
| Gram reactivity | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |
| Strong acid-fastness | 18 | 18 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Weak or partial acid- | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 60 | 100 | 0 | 0 | |
| fastness | | | | | | | | | | | | |
| Permanent mycelium | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Fragmenting mycelium | Ŏ | Ō | Ō | 9 | Ō | 0 | 0 | 20 | 78 | 25 | 0 | |
| Long rods (>7 μ m long) | Ō | Ō | 14 | 9 | Ō | 0 | 20 | 60 | 78 | 100 | 0 | |
| Intermediate rods | 36 | 73 | 100 | 100 | 100 | 100 | 100 | 100 | 78 | 100 | 13 | |
| (3-6 µm long) | | | | | | | | | | | | |
| Short rods ($<2 \mu m \log$) | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 78 | 100 | 100 | |
| Cross bars of the cell | 0 | 9 | 29 | 0 | 0 | 33 | 20 | 20 | 0 | 0 | 0 | |
| Cord formation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Rough colonies | 100 | 100 | 100 | 91 | 89 | 89 | 100 | 80 | 100 | 75 | 0 | |
| Colony pigmentation in | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |
| the dark | | | | | | | | | | | | |
| Photochromogenicity | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Growth | | | | | | | | | | | | |
| After 3 days | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |
| 28°C | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |
| 37°C | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |
| 42°C | 91 | 9 | 100 | 45 | 0 | 0 | 80 | 40 | 44 | 0 | 25 | |
| 45°C | 27 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 52°C | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Resistance to 0.2% sodium <i>p</i> -aminosalicy- | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |
| Degradation of <i>p</i> -amino- salicylate to catechol Resistance to | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| $NH_2OH \cdot HCI$ | | | | | | | | | | | | |
| 125 μg/ml | 100 | 100 | 86 | 91 | 100 | 78 | 100 | 100 | 100 | 100 | 100 | |
| 250 μg/ml | 91 | 100 | 0 | 9 | 33 | 0 | 40 | 0 | 100 | 75 | 100 | |
| 500 μg/ml | 45 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | /8 | 0 | 100 | |
| Growth on modified | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |
| Sauton agar medium | 100 | 100 | 71 | 100 | 100 | 100 | 100 | 100 | 90 | 50 | 25 | |
| Tolerance to 0.1% | 100 | 100 | /1 | 100 | 100 | 100 | 100 | 100 | 89 | 50 | 25 | |
| sodium salicylate | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ٥ | |
| late to catechol | 0 | U | U | U | U | U | U | U | U | U | U | |
| | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 50 | 20 | |
| 0.1% | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 50 | 38 20 | |
| 0.2% Arrulaulfatasa | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 25 | 30 | |
| A dovo | ٥ | ٥ | ٥ | 0 | ٥ | ٥ | 0 | ٥ | 0 | ٥ | ٥ | |
| 14 days | 0 | 19 | 0 | 0 | 0 | 22 | 0 | 0 | 0 | 0 | 0 | |
| Resistance to thiophene- 2-caroxylic acid | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |
| hydrazide (10 µg/ml) Resistance to salicylate | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |
| (0.5 mg/ml) Resistance to ethambu- | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 80 | 11 | 0 | 75 | |
| tol (5 μg/ml) Tolerance to sodium nitrite | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 00 | | v | 15 | |
| 0.1% | 100 | 100 | 100 | 100 | 100 | 11 | 100 | 80 | 100 | 25 | 13 | |
| 0.2% | 100 | 82 | 100 | 100 | 100 | 0 | 0 | 80 | 56 | 0 | Ő | |
| Tolerance to 1% Tween 80 | 100 | 100 | 100 | 100 | 100 | 67 | 100 | 0 | 78 | Ő | 63 | |
| Resistance to <i>p</i> -nitro- benzoic acid (0.5 mg/ml) | 91 | 100 | 100 | 100 | 100 | 44 | 60 | 100 | 100 | 0 | 38 | |
| Resistance to rifampin (25 µg/ml) | 82 | 82 | 0 | 64 | 89 | 44 | 0 | 0 | 0 | 0 | 13 | |
| Niacin production | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |

Continued on following page

| | % of strains with character ^b | | | | | | | | | | | |
|--------------------------------|--|---|------------------------|-----------------------------|-------------------------------------|---------------------|--------------------------|------------------------|------------------------------------|---------------------------------|--------------------|--|
| Character | Present isolates (n = 11) | <i>R. aur-</i> <i>antiacus</i> (<i>n</i> = 11) | R. bron-chialis(n = 7) | R. rubro-pertinctus(n = 11) | <i>R. terrae</i> (<i>n</i> = 9) | R. sputi (n = 9) | R. aichiensis (n = 5) | R. rho-dochrous(n = 5) | R. lenti- fragmentus (n = 9) | R. eryth- ropolis (n = 4) | R. equi (n = 8) | |
| Tween 80 hydrolysis | | | | | | | | | | | | |
| 7 days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ٥ | |
| 14 days | 27 | 100 | ŏ | sš | 67 | 11 | 40 | ŏ | Ő | ŏ | 13 | |
| Catalase (foam height | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |
| more than 45 mm) | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |
| a-Esterase activity | ٥ | 0 | ٥ | 45 | 100 | 33 | ٥ | ٥ | 0 | 0 | 50 | |
| B-Esterase activity | 64 | Ň | 43 | 55 | 100 | 0 | 0 | Ň | 0 | 0 | 50 | |
| B-Galactosidase activity | 18 | 100 | | 0 | 100 | 0 | 0 | 0 | 0 | 0 | 50 | |
| Acid phosphatase | 55 | 73 | 100 | Ň | Ň | 100 | 100 | 60 | 0 | 100 | 100 | |
| activity | 55 | 15 | 100 | U | 0 | 100 | 100 | 00 | U | 100 | 100 | |
| Nitrate reduced to | | | | | | | | | | | | |
| nitrite | | | | | | | | | | | | |
| 6 h | 36 | 0 | 100 | 82 | 100 | 44 | 100 | 100 | 100 | ٥ | 100 | |
| 24 h | 36 | ň | 100 | 82 | 100 | 44 | 100 | 100 | 100 | Ŏ | 100 | |
| Acetamidase activity | 100 | 100 | 100 | 02 | 100 | 78 | 80 | 100 | 100 | 75 | 100 | |
| Renzamidase activity | 100 | 100 | 100 | Ň | Ő | /0 | 0 | 0 | 100 | ,5 | 100 | |
| Urease activity | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 20 | 0 | 100 | 15 | |
| Isonicotinamidase | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 20 | 0 | 100 | 0 | |
| activity | U | U | U | U | U | U | U | U | 0 | U | U | |
| Nicotinamidase activity | 100 | 100 | 71 | 0 | 100 | 80 | 100 | ٥ | 100 | 0 | 0 | |
| Pyrazinamidase activity | 100 | 100 | 71 | 9 | 100 | 79 | 100 | 0 | 100 | 0 | 12 | |
| Salicylamidase activity | 100 | 100 | /1 | 9 | 100 | /0 | 100 | 0 | 100 | 0 | 15 | |
| Allentoinese activity | 01 | 100 | 0 | 100 | 100 | 54 | 100 | 0 | 0 | 0 | 0 | |
| Succinamidase activity | 91 | 100 | 0 | 100 | 100 | 50 | 100 | 0 | 0 | 0 | 0 | |
| L Glutamate as simulta- | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 25 | 62 | |
| neous N and C source | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 25 | 05 | |
| L Serine as simulto | 01 | 100 | ٥ | 0 | 44 | 80 | 100 | 0 | | 0 | 0 | |
| L-Serine as simula- | 91 | 100 | U | 9 | 44 | 09 | 100 | U | 44 | U | U | |
| Chaosemine as simulte | 01 | 100 | 42 | 01 | 100 | 54 | 60 | 60 | 70 | 0 | 0 | |
| Diucosainine as siniuita- | 91 | 100 | 43 | 91 | 100 | 30 | 00 | 00 | /8 | U | U | |
| A cetomide as simulto | 100 | 100 | 100 | 0 | 0 | 100 | 100 | 0 | (7 | 0 | 75 | |
| Acetainiue as simulta- | 100 | 100 | 100 | U | U | 100 | 100 | U | 0/ | U | 15 | |
| Repromide of simulto | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 51 | 0 | • | |
| neous N and C source | U | U | U | 0 | U | U | U | U | 20 | U | U | |
| Monoethoolomine of | 100 | 100 | 0 | 100 | 100 | 70 | 100 | 0 | 100 | 0 | 12 | |
| simultaneous N and C | 100 | 100 | U | 100 | 100 | /0 | 100 | U | 100 | U | 15 | |
| | | | | | | | | | | | | |
| Trimethylene diamine as | ٥ | 0 | 0 | 0 | ٥ | 0 | ٥ | ٥ | 0 | 0 | 0 | |
| simultaneous N and C | U | U | U | U | U | U | U | U | U | U | U | |
| | | | | | | | | | | | | |
| Chucese on C course | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |
| (dutomate for N) | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |
| (glutaliate Iol IN) | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |
| (dutomoto for N) | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |
| (giutaliate IOI IN) | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |
| Succinate as C source | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |
| (giulamate for N) | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |
| Pyruvale as C source | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |
| (giutaliate for N) | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |
| Citrate as C source | 100 | 100 | 100 | 100 | 100 | 67 | 100 | 100 | 100 | 100 | 100 | |
| Citrate as C source | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 40 | /0 | 100 | 100 | |
| Malata as C source | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |
| Malate as C source | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |
| Pyruvale as C source | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |
| Melanate as C source | 10 | 33 | 57 | 100 | 100 | 11 | 0 | 00 | 100 | 0 | 0 | |
| Furnemente as C source | 100 | 100 | 100 | 100 | 100 | 80 | 20 | 80 | 100 | 100 | 80 | |
| Fumarate as C source | 100 | 100 | 100 | 100 | 100 | 100 | 20 | 100 | 100 | 100 | 100 | |
| Glucose as C source | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |
| Sucrose as C source | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 88 | |
| Ethonol on C source | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 90 90 | 100 | 100 | 100 | |
| Emanoi as C source | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |
| <i>n</i> -rropanoi as C source | 100 | 100 | 100 | 100 | 47 | 100 | 200 | 100 | 200 | 75 | 88 | |
| C source | 100 | 91 | 100 | U | 07 | 22 | 20 | | 07 | 15 | 00 | |
| 1 3-Butylene alvool oo | Δ | ٥ | Δ | 87 | າາ | Λ | 20 | n | 0 | n | 0 | |
| C source | U | v | v | 02 | | v | 20 | v | v | v | v | |
| C SULLE | | | | | | | | | | | | |

TABLE 1-Continued

Continued on following page

| | % of strains with character ^h | | | | | | | | | | | |
|--|--|---------------------------------|--------------------------------|-------------------------------------|----------------------|---------------------|--------------------------|------------------------|------------------------------------|---------------------------------|--------------------|--|
| Character | Present isolates (n = 11) | R. aur- antiacus (n = 11) | R. bron- chialis (n = 7) | R. rubro- pertinctus (n = 11) | R. terrae (n = 9) | R. sputi (n = 9) | R. aichiensis (n = 5) | R. rho-dochrous(n = 5) | R. lenti- fragmentus (n = 9) | R. eryth- ropolis (n = 4) | R. equi (n = 8) | |
| 1,4-Butylene glycol as C source | 100 | 0 | 14 | 82 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 2,3-Butylene glycol as C source | 100 | 91 | 29 | 82 | 44 | 100 | 100 | 100 | 44 | 50 | 0 | |
| n-Butanol as C source | 100 | 100 | 100 | 0 | 100 | 100 | 80 | 100 | 100 | 25 | 100 | |
| iso-Butanol as C source | 100 | 100 | 100 | 0 | 100 | 100 | 80 | 100 | 100 | 25 | 100 | |
| Acid from glucose | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 0 | |
| Acid from mannose | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 0 | |
| Mannose as C source | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 38 | |
| p-Galactose as C source | 100 | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| L-Arabinose as C source | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| D-Xvlose as C source | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| L-Rhamnose as C source | Ō | Ó | 0 | 0 | 100 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Trehalose as C source | 100 | 100 | 100 | 100 | 100 | 89 | 100 | 0 | 78 | 0 | 0 | |
| Inositol as C source | 91 | 100 | 100 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Mannitol as C source | 55 | 100 | 0 | 100 | 100 | 100 | 60 | 0 | 100 | 0 | 0 | |
| Sorbitol as C source | 55 | 100 | Ō | 100 | 100 | 100 | 60 | 0 | 100 | 0 | 0 | |
| L-Serine as N source | 100 | 100 | 43 | 91 | 100 | 100 | 100 | 20 | 100 | 0 | 0 | |
| Acetamide as N source | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 60 | 100 | 0 | 0 | |
| Benzamide as N source | 0 | 0 | 0 | 18 | 67 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Urea as N source | 91 | 100 | 86 | 100 | 100 | 100 | 100 | 20 | 100 | 0 | 0 | |
| Pyrazinamide as N source | 91 | 100 | 71 | 73 | 100 | 100 | 100 | 0 | 100 | 0 | 0 | |
| Nicotinamide as N source | 82 | 100 | 100 | 91 | 100 | 100 | 100 | 0 | 100 | 0 | 0 | |
| Succinamide as N source | 91 | 100 | 57 | 100 | 100 | 11 | 40 | 0 | 67 | 0 | 0 | |
| Nitrate as N source | 91 | 100 | 100 | 100 | 100 | 100 | 100 | 20 | 100 | 0 | 0 | |
| Nitrite as N source | 0 | 18 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Resistance to 5% NaCl | 100 | 100 | 71 | 100 | 100 | 100 | 100 | 80 | 22 | 0 | 88 | |
| Resistance to isoniazid (10 µg/ml) | 82 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |
| Resistance to ofloxacin (1 µg/ml) | 82 | 82 | 57 | 36 | 89 | 100 | 20 | 100 | 78 | 0 | 88 | |
| Resistance to ofloxacin (5 µg/ml) | 27 | 0 | 0 | 0 | 0 | 11 | 0 | 40 | 0 | 0 | 0 | |
| Resistance to 5-fluoro- uracil (20 µg/ml) | 100 | 100 | 0 | 0 | 22 | 11 | 0 | 0 | 11 | 0 | 50 | |
| Resistance to mitomycin C (5 µg/ml) | 100 | 100 | 100 | 0 | 100 | 33 | 0 | 20 | 0 | 0 | 0 | |

TABLE 1—Continued

^{*a*} Unless specially noted, the utilization of carbohydrates as sole carbon sources was tested in the presence of ammoniacal nitrogen, and the utilization of nitrogen compounds as sole nitrogen sources was tested in the presence of glycerol as a carbon source. Resistances were tested in Ogawa egg medium, and tolerances were tested in a modified Sauton agar medium. The composition of the modified Sauton agar medium is as follows: glycerol, 30 ml; KH₂PO₄, 0.5 g; MgSO₄ · 7H₂O, 0.5 g; citric acid, 2.0 g; ferric ammonium citrate, 0.05 g; agar, 20.0 g; distilled water, 970 ml. The pH was adjusted to 7.0 by adding a 10% NaOH Solution.

^b The number of strains tested is shown in parentheses.

agreement of the tests with those for the prototype of the species.

RESULTS

The isolates appeared to be slightly acid-fast short rods and did not form mycelium, suggesting that the isolates belonged to the genus *Rhodococcus* (3, 7). On subculture, they grew on Ogawa egg medium after 3 days of incubation and formed rough, slightly brownish or orange-pigmented colonies, forming no spore and growing only under aerobic conditions. The isolates were identified as *R. aurantiacus*, showing 90 to 96% agreement with the reactions of the type strain. Reaction concordance with other rhodococci was at most 82%. Comparison of the characters of the isolates with the control *R. aurantiacus* strains and with other rhodococci is shown in Table 1. The susceptibilities to various antituberculosis drugs were determined in Ogawa egg medium, inoculating 0.1 mg (wet weight) of an isolate and incubating the inoculated slants at 37° C for 3 days. The isolates were resistant to streptomycin (200 µg/ml), isoniazid (200 µg/ml), ethionamide (200 µg/ml), and ethambutol (50 µg/ml). They showed the following MICs: rifampin, 100 µg/ml; kanamycin, 400 µg/ml; enviomycin (tuberactinomycin N; Toyo Jozo Co., Shizuoka, Japan), 400 µg/ml; kitasamycin (leucomycin; Toyo Jozo Co., Shizuoka, Japan), 25 µg/ml; sulfadimethoxine, 12.5 µg/ml; and minocycline, 3.13 µg/ml.

DISCUSSION

The pus of the patient yielded only *R. aurantiacus* consistently. All other bacteria were isolated sporadically and were considered contaminants. *R. aurantiacus* strains are resistant to most antibiotics and antibacterial substances, as demonstrated by the clinical failure of most drug regimens in this patient. The persistence of R. aurantiacus and its drug resistance suggest that it is the etiological agent in this patient. Two cases of infections caused by this organism have been reported (1, 5). The first involved a lung infection that was not cured but had a remission (5). The second was a fatal meningitis (1). The present case is a very severe, gangrenous tenosynovitis with multiple subcutaneous abscesses. In our case, various drug regimens have been used, but until now the chemotherapeutic treatment seems to have been unsuccessful.

We reported that β -galactosidase activity is important in identifying this organism (5). However, the present isolates did not show this activity. Even without β-galactosidase activity, identification is based on the following characteristics: (i) growth of subculture after 3 days, forming rough, brownish (or orange-pigmented) colonies; (ii) the bacteria are slightly acid-fast rods (at most 5 µm in length) and do not form mycelium (some strains occur as strongly acid-fast short rods); (iii) they tolerate 0.2% picric acid and 0.2% sodium nitrite in a modified Sauton agar medium, in which sodium glutamate has been substituted for asparagine; (iv) they do not show arylsulfatase activity after 14 days; (v) they do not reduce nitrate to nitrite; (vi) they utilize sucrose as a sole carbon source in the presence of ammoniacal nitrogen; (vii) they utilize galactose as a sole carbon source in the presence of ammoniacal nitrogen; and (viii) they are resistant to 5-fluorouracil (20 μ g/ml) and to mitomycin C (5 μ g/ml) in Ogawa egg medium (or Lowenstein-Jensen medium).

LITERATURE CITED

- 1. Prinz, G., E. Bán, S. Fekete, and Z. Szabó. 1985. Meningitis caused by *Gordona aurantiaca* (*Rhodococcus aurantiacus*). J. Clin. Microbiol. 22:472-474.
- Tsukamura, M. 1981. Numerical analysis of rapidly growing, nonphotochromogenic mycobacteria, including *Mycobacterium* agri (Tsukamura 1972) Tsukamura sp. nov., nom. rev. Int. J. Syst. Bacteriol. 31:247-258.
- Tsukamura, M. 1982. Numerical analysis of the taxonomy of nocardiae and rhodococci. Division of Nocardia asteroides sensu stricto into two species and descriptions of Nocardia paratuberculosis sp. nov. Tsukamura (formerly the Kyoto-I group of Tsukamura), Nocardia nova sp. nov. Tsukamura, Rhodococcus aichiensis sp. nov. Tsukamura, Rhodococcus chubuensis sp. nov. Tsukamura, and Rhodococcus obuensis sp. nov. Tsukamura. Microbiol. Immunol. 26:1101-1119.
- Tsukamura, M. 1967. Identification of mycobacteria. Tubercle 48:311-338.
- Tsukamura, M., and K. Kawakami. 1982. Lung infection caused by Gordona aurantiaca (Rhodococcus aurantiacus). J. Clin. Microbiol. 16:604–607.
- Tsukamura, M., and S. Mizuno. 1971. A new species Gordona aurantiaca occurring in sputa of patients with pulmonary disease. Kekkaku 46:93-98.
- Tsukamura, M., and I. Yano. 1985. Rhodococcus sputi sp. nov., nom. rev., and Rhodococcus aurantiacus sp. nov., nom. rev. Int. J. Syst. Bacteriol. 35:364–368.